The Animal AgTech Innovation Summit drew 450 executives from 22 countries to Fort Worth last week. The programming told a clear story: an industry sitting on a generational protein demand tailwind, confronting existential biosecurity threats, and still unable to close the gap between what technology can do and what producers will actually use.
Three forces shaped the conversation. Disease risk has moved from cost center to investment category. The venture capital model is losing credibility for commodity agriculture. And the last mile of technology adoption remains unsolved, despite a decade of sensor proliferation.
Biosecurity is Now an Investment Thesis
The summit opened with a biosecurity panel that read like a threat briefing. HPAI. African Swine Fever. PRRS. BRD. The return of New World Screwworm on the US-Mexico border.
The question posed to the room was whether the industry faces a future animal pandemic. The panelists, spanning Boehringer Ingelheim, Oklahoma State, the National Pork Board, and Texas A&M, treated this as a matter of when, not if.
What's changed is the framing. Biosecurity used to be a regulatory compliance exercise. Fort Worth positioned it as a technology market: rapid diagnostics, digital surveillance, barn-level pathogen removal, mRNA and RNAi vaccine platforms adapted for livestock.
The startup showcase reinforced this. Daro pitched whole-herd molecular surveillance. KiposTech demonstrated an AI-enabled air quality system that neutralizes airborne pathogens inside barns. ProtonDx showed a portable pathogen testing platform for on-farm use.
Boehringer Ingelheim, the world's second-largest animal health company, committed 22.9% of group net sales to R&D in 2025 and sent its VP of Livestock Business to the main stage. The incumbents see white space. So should investors.
The VC Model is Being Questioned
The capital that is flowing has changed character. The panel featured Banneker Partners (PE, vertical software thesis), Fulcrum Global Capital, and Strength Capital Partners alongside The Yield Lab Institute. The conversation centered on PE and corporate venture models, not traditional VC.
Two speakers embodied the shift:
Stephen Davis (Banneker Partners) brings the Vista Equity Partners playbook to food and ag. His portfolio includes Ever.Ag and Silo Technologies. The thesis is vertical SaaS, not deeptech moonshots.
Dan Griffis (ADM Ventures) represents the corporate VC approach, investing in platform technologies that span human and animal nutrition.
Meanwhile, OEMs like Deere and CNH are acquiring agtech startups at depressed valuations. The funding environment is not frozen. It is reorganizing around different risk tolerances and shorter payback periods.
Record beef prices create a narrow window here. High margins make producers more willing to spend on technology. But the fragmented US cattle sector, with its 86.2 million head spread across thousands of independent operations, remains structurally hard to penetrate at scale.
The Adoption Gap Nobody Has Solved
The most revealing programming choice was how many sessions addressed not what technology can do, but why it isn't being used.
A farmers and ranchers spotlight put four working producers on the main stage to articulate daily operational challenges. Three separate roundtables tackled the soft side of agtech (behavior change on farms), the information gap (why more livestock data hasn't meant more progress), and AI's practical limitations in food production.
The uncomfortable reality: sensor proliferation has not translated to proportional productivity gains. The bottleneck is not data collection. It is decision support, system integration, and farmer workflows.
For founders, this is the signal. Companies that solve the last mile of adoption will command disproportionate value. Companies that add another dashboard to the stack will not.
What to Watch
Several structural shifts surfaced at Fort Worth that will matter over the next 12 to 36 months:
Methane reduction must now be privately financed. The summit noted explicitly that US climate grants are no longer active. Corporate Scope 3 targets from companies like Danone are now the primary demand signal. Rumin8, Athian, and Agteria BioTech are positioned here, but the economics without subsidies remain unproven.
Gene editing has cleared regulatory thresholds. FDA-approved PRRS-resistant pigs are a landmark. Consumer trust, not science, is now the binding constraint. Alison Van Eenennaam (UC Davis) and panelists from Cobb-Vantress, Semex, and Leachman Cattle explored how to close that gap.
Tariff exposure is material. Feed ingredient supply chains dependent on China, plus retaliatory tariffs on US protein exports, create risk that most operators have not priced in.
Water is becoming a first-order constraint for livestock operations, not an ESG checkbox. Dedicated sessions on smart meters, leak detection, and aquifer recharge reflect drought conditions tightening across cattle country.
Graphic from ReThink - A WilliamReed Company